Seeking Alpha

BioTime unit gets grant for development of AMD treatment

  • BioTime (BTX +2.3%) subsidiary Cell Cure Neurosciences gets a $1.74M grant for 2014 from Israel's OCS.
  • The funds will be used to develop OpRegen for the treatment of AMD.
  • The company intends to complete preclinicals and file an IND for the commencement of human trials next year.
  • Cell Cure notes that it will repay the grant plus interest via royalty payments to OCS. (PR)
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector